Genome patent overturned

Written byAndrea Gawrylewski

| 1 min read

Listen with Speechify

0:00

1:00

Yesterday the British High Court overturned a UK genome patent owned by biotech Human Genome Sciences. The patent covered the inflammation-linked protein neutrokine-alpha which is part of the tumor necrosis factor family of cytokines. The court overturned the patent, ruling that at the time its application was filed there was no practical application, the Financial Times linkurl:reported.;http://www.ft.com/cms/s/0/c2649894-5f54-11dd-91c0-000077b07658.html?nclick_check=1 Human Genome Sciences applied for the patent in the mid-1990s. But the ruling might really affect Eli Lilly, who has spent $50 million developing an antibody to neutrokine-alpha and is looking to spend another $250 million bringing the therapy through clinical trials, the Times reported.

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!

Join for free today

Already a member? Login Here